MGTA - Magenta Therapeutics up 47% on plan to pursue strategic alternatives
- Magenta Therapeutics ( NASDAQ: MGTA ) has added 47% in post-market trading after saying it will stop development of its program and conduct a review of strategic alternatives.
- These alternatives can include an acquisition, merger, or business combination.
- Over the last year through Thursday's close, shares are down 83% .
- Seeking Alpha's Quant Rating views Magenta ( MGTA ) as a hold.
For further details see:
Magenta Therapeutics up 47% on plan to pursue strategic alternatives